Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Hemoglobin A1c and Fructosamine Evaluated in Patients with Type 2 Diabetes Receiving Peritoneal Dialysis Using Long-Term Continuous Glucose Monitoring

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Improved Glucose Tolerance after High-Load Strength Training in Patients Undergoing Dialysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Liraglutide versus colesevelam for treating bile acid diarrhoea – Authors' reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mapping prohormone processing by proteases in human enteroendocrine cells using genetically engineered organoid models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Shortened erythrocyte life span and erythropoietin-stimulating agents may affect hemoglobin A1c (HbA1c) levels in patients receiving peritoneal dialysis (PD). We compared HbA1c with interstitial glucose measured by continuous glucose monitoring (CGM) in patients with type 2 diabetes receiving PD.

METHODS: Fourteen days of CGM (Ipro2, Medtronic) were performed in 23 patients with type 2 diabetes receiving PD and in 23 controls with type 2 diabetes and an estimated glomerular filtration rate over 60 mL/min/1.73 m2. Patients were matched on gender and age (±5 years). HbA1c (mmol/mol), its derived estimate of mean plasma glucose (eMPGA1c) (mmol/L), and fructosamine (µmol/L) were measured at the end of the CGM period and compared with the mean sensor glucose (mmol/L) from CGM.

RESULTS: In the PD group, mean sensor glucose was 0.98 (95% con-fidence interval (CI): 0.43-1.54) mmol/L higher than the eMPGA1c compared with the control group (p = 0.002) where glucose levels were nearly identical (-0.05 (95% CI: -0.35-0.25) mmol/L). A significant association was found between fructosamine and mean sensor glucose using linear regression with no difference between slopes (p = 0.89) or y-intercepts (p = 0.28).

DISCUSSION/CONCLUSION: HbA1c underestimates mean plasma glucose levels in patients with type 2 diabetes receiving PD. However, the clinical significance of this finding is undetermined. Fructosamine seems to more accurately reflect glycemic status. CGM or fructosamine could complement HbA1c to increase the accuracy of glycemic monitoring in the PD population.

OriginalsprogEngelsk
TidsskriftNephron
Vol/bind146
Udgave nummer2
Sider (fra-til)146-152
Antal sider7
ISSN0028-2766
DOI
StatusUdgivet - 2022

Bibliografisk note

© 2021 S. Karger AG, Basel.

ID: 68727451